医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

OPTIC-J

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Clinical Trial OPTIC-J TED TEPEZZA teprotumumab-trbw

2022年11月16日

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Clinical Trial Horizon Therapeutics plc Initiates Phase OPTIC-J TED

2022年02月23日